Prescient Therapeutics (ASX:PTX) share price flat after trial success news

Shares in the clinical stage oncology company have clawed back some ground after falling in early trade this morning

A health professional sits contemplating in the corridor of a hospital.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Prescient Therapeutics Ltd (ASX: PTX) share price is having a lacklustre day, despite a positive readout on its PTX-100 trial.

Prescient shares dipped into the red in morning trade. However, at the time of writing they are exchanging hands for 22 cents a piece, the same as yesterday's closing price.

Let's take a look at what Prescient released this morning.

Quick refresher on Prescient Therapeutics

Prescient is a clinical stage oncology company that researches, develops and commercialises new cancer treatments.

It has expertise in the treatment of myeloma, pancreatic and breast cancer. It also collaborates with larger players to develop its proprietary products.

Prescient has a market capitalisation of $138 million at the time of writing.

PTX-100 basket trial results

Prescient released the readouts from its PTX-100 phase 1b basket trial earlier today. The purpose of a phase 1b trial is to determine the optimal safe dose for a new therapy.

As such, the trial examined the safety of the PTX-100 compound, which Prescient is studying for solid and haematological tumours.

In the trial, PTX-100 "exhibited an excellent safety profile … up to and including the highest dose", with no adverse events "deemed serious, nor related to PTX-100".

Another takeout is that two patients also received a "clinical benefit" after a run of failed prior treatments for their condition.

Both patients benefitted from "symptomatic relief" and a "reduction in cancer burden with no disease progression".

Prescient now intends to begin a cohort study to develop PTX-100 as a monotherapy, hoping to create a "potentially shorter regulatory path" for the compound.

Investors can expect further readouts from this study in the coming quarter, as per the company.

Prescient share price snapshot

The Prescient Therapeutics share price has posted a year-to-date return of about 215%, extending the previous 12 month's return of 268%.

These returns have far outpaced the S&P/ASX 200 Index (ASX: XJO)'s return of 23% over the past year.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Two men in hard hats and high visibility jackets look together at a laptop screen at a mine site.
Gold

Down 50% in a year, time to pounce on this beaten-down ASX 200 gold stock?

A leading expert offers his verdict on this beaten-down ASX 200 gold miner.

Read more »

A view of competitors in a running event, some wearing number bibs, line up together on a starting line looking ahead as if to start a race.
Best Shares

Best ASX 200 share of each market sector in FY25

Did you own any of these ASX 200 winners in FY25?

Read more »

children and teacher in childcare education setting
Broker Notes

Why did Macquarie just re-rate G8 Education shares?

G8 Education shares are down 23% this year.

Read more »

IPO written in yellow and stuck in the air.
IPOs

End of the IPO drought: GemLife listing one of the biggest of the year

The GemLife IPO is the third major ASX listing in less than a month.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Share Market News

Why brokers says these ASX dividend stocks are top buys for income investors

Want an income boost? Take a look at these stocks that brokers rate as buys.

Read more »

A man looking at his laptop and thinking.
Broker Notes

After crashing more than 21% yesterday, does Macquarie rate Helia shares a buy?

Should I buy the big dip on Helia shares? Here’s Macquarie’s latest share price forecast.

Read more »

Happy work colleagues give each other a fist pump.
Broker Notes

Buy this ASX 200 share that is having a 'milestone year'

Bell Potter has good things to say about this high-flying stock.

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why Domino's, NRW, Pro Medicus, and WIA Gold shares are charging higher today

These shares are avoiding the market weakness and are pushing higher today. But why?

Read more »